Sanofi And Hengrui To Go To Court Again
This article was originally published in PharmAsia News
In response to the verdict of non-patent infringement of Hengrui's use of docetaxel in China, Sanofi-Aventis is likely to appeal to the Beijing Number One Intermediate People's Court to further fight for its patent rights. The Greater China office says that it cannot comment on the case now but states that Sanofi holds the patent for docetaxel worldwide and its team of lawyers is preparing the necessary legal documents. Industry observers believe Sanofi is not likely to give up its fight for the patent as Taxotere, its key antitumor product using docetaxel, fetches a lucrative profit. (Click here for more - Chinese Language)
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.